Screener
Alkermes ALKS R&D
R&D at other companies
Other financials
Where this comes from
Reported directly by Alkermes in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Alkermes’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 9:22 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-319022
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Total revenues | 496,009 | 390,657 | 888,920 | 697,167 |
| EXPENSES: | ||||
| Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below) | 98,112 | 49,460 | 159,690 | 98,657 |
| Research and development | 112,920 | 77,370 | 216,265 | 149,187 |
| Selling, general and administrative | 217,625 | 170,849 | 482,218 | 342,553 |
| Change in fair value of contingent consideration | 26,414 | — | 26,414 | — |
| Amortization of acquired intangible assets | 22,585 | — | 34,260 | — |
| Total expenses | 477,656 | 297,679 | 918,847 | 590,397 |
Item 1. Condensed Consolidated Financial Statements:
FAQ
- What is Alkermes's R&D?
- Alkermes (ALKS) reported R&D of $112.92M in Q2 2026.
- How has Alkermes's R&D changed year-over-year?
- Alkermes's R&D increased by 45.9% year-over-year, from $77.37M to $112.92M.
- What is the long-term trend for Alkermes's R&D?
- Over 4 years (2021 to 2025), Alkermes's R&D has grown at a -5.5% compound annual growth rate (CAGR), from $406.53M to $323.96M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Alkermes's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude